Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

Similar articles for PubMed (Select 21148040)

1.

Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.

Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P.

J Immunol. 2011 Jan 15;186(2):807-15. doi: 10.4049/jimmunol.1001483. Epub 2010 Dec 8.

2.

Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages.

Morias Y, Abels C, Laoui D, Van Overmeire E, Guilliams M, Schouppe E, Tacke F, deVries CJ, De Baetselier P, Beschin A.

PLoS Pathog. 2015 May 28;11(5):e1004873. doi: 10.1371/journal.ppat.1004873. eCollection 2015 May.

3.

BRAF-inhibition and tumor immune suppression.

Steinberg SM, Turk MJ.

Oncoimmunology. 2015 Mar 6;4(2):e988039. eCollection 2015 Feb. Review.

PMID:
25949884
4.

Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression.

van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, van der Burg SH, van Hall T.

Cancer Immunol Res. 2015 Apr 17. pii: canimm.0052.2015. [Epub ahead of print]

PMID:
25888578
5.

Specific depletion of Ly6C(hi) inflammatory monocytes prevents immunopathology in experimental cerebral malaria.

Schumak B, Klocke K, Kuepper JM, Biswas A, Djie-Maletz A, Limmer A, van Rooijen N, Mack M, Hoerauf A, Dunay IR.

PLoS One. 2015 Apr 17;10(4):e0124080. doi: 10.1371/journal.pone.0124080. eCollection 2015.

6.

The emerging understanding of myeloid cells as partners and targets in tumor rejection.

Broz ML, Krummel MF.

Cancer Immunol Res. 2015 Apr;3(4):313-9. doi: 10.1158/2326-6066.CIR-15-0041. Review.

PMID:
25847968
7.

Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer.

Son CH, Bae JH, Shin DY, Lee HR, Jo WS, Yang K, Park YS.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):390-8. doi: 10.1016/j.ijrobp.2015.01.011. Epub 2015 Mar 5.

PMID:
25754628
8.

Differential induction of Ly6G and Ly6C positive myeloid derived suppressor cells in chronic kidney and liver inflammation and fibrosis.

Höchst B, Mikulec J, Baccega T, Metzger C, Welz M, Peusquens J, Tacke F, Knolle P, Kurts C, Diehl L, Ludwig-Portugall I.

PLoS One. 2015 Mar 4;10(3):e0119662. doi: 10.1371/journal.pone.0119662. eCollection 2015.

9.

Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells.

Arina A, Bronte V.

Curr Opin Immunol. 2015 Apr;33:120-5. doi: 10.1016/j.coi.2015.02.006. Epub 2015 Feb 27. Review.

PMID:
25728992
10.

Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.

Ortiz ML, Kumar V, Martner A, Mony S, Donthireddy L, Condamine T, Seykora J, Knight SC, Malietzis G, Lee GH, Moorghen M, Lenox B, Luetteke N, Celis E, Gabrilovich D.

J Exp Med. 2015 Mar 9;212(3):351-67. doi: 10.1084/jem.20140835. Epub 2015 Feb 9.

PMID:
25667306
11.

Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.

Tongu M, Harashima N, Tamada K, Chen L, Harada M.

Cancer Sci. 2015 Jan;106(1):9-17. doi: 10.1111/cas.12568. Epub 2014 Dec 9.

PMID:
25363339
12.

Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number.

Rossowska J, Pajtasz-Piasecka E, Anger N, Wojas-Turek J, Kicielińska J, Piasecki E, Duś D.

J Immunother. 2014 Nov-Dec;37(9):427-39. doi: 10.1097/CJI.0000000000000054.

PMID:
25304726
13.

iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.

Jayaraman P, Alfarano MG, Svider PF, Parikh F, Lu G, Kidwai S, Xiong H, Sikora AG.

Clin Cancer Res. 2014 Dec 15;20(24):6439-51. doi: 10.1158/1078-0432.CCR-13-3409. Epub 2014 Oct 2.

PMID:
25278453
14.

Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S.

J Leukoc Biol. 2014 Dec;96(6):1109-18. doi: 10.1189/jlb.3A0414-210R. Epub 2014 Aug 28.

PMID:
25170116
15.

Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells.

Wondimu A, Liu Y, Su Y, Bobb D, Ma JS, Chakrabarti L, Radoja S, Ladisch S.

Cancer Res. 2014 Oct 1;74(19):5449-57. doi: 10.1158/0008-5472.CAN-14-0927. Epub 2014 Aug 12.

PMID:
25115301
16.

Preface for The year in immunology: myeloid cells and inflammation.

Rose NR.

Ann N Y Acad Sci. 2014 Jun;1319:v-vi. doi: 10.1111/nyas.12495. No abstract available.

PMID:
24965259
17.

[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].

Bruchard M, Ghiringhelli F.

Bull Cancer. 2014 Jun;101(6):605-7. doi: 10.1684/bdc.2014.1936. Review. French.

PMID:
24899072
18.

Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.

J Immunol. 2014 Jun 15;192(12):5821-9. doi: 10.4049/jimmunol.1400404. Epub 2014 May 7.

19.

Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.

Ding ZC, Lu X, Yu M, Lemos H, Huang L, Chandler P, Liu K, Walters M, Krasinski A, Mack M, Blazar BR, Mellor AL, Munn DH, Zhou G.

Cancer Res. 2014 Jul 1;74(13):3441-53. doi: 10.1158/0008-5472.CAN-13-3596. Epub 2014 Apr 29.

20.

Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection.

Heim CE, Vidlak D, Scherr TD, Kozel JA, Holzapfel M, Muirhead DE, Kielian T.

J Immunol. 2014 Apr 15;192(8):3778-92. doi: 10.4049/jimmunol.1303408. Epub 2014 Mar 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk